IDENTIFICATION OF DIFFERENTLY EXPRESSED GENES AND MOLECULAR PATHWAYS ASSOCIATED WITH BREAST CANCER PROGRESSION

Authors

  • Dr Anyanwu Chidimma Gogo Chemical Society of Nigeria University: Kingsley Ozumba Mbadigwe University Ogboko, Nigeria.

DOI:

https://doi.org/10.67772/fer7tg76

Keywords:

Breast cancer, Differential gene expression, Tumor stage, Molecular pathways, Prognosis

Abstract

A complex interaction among clinicopathological characteristics and molecular alterations, is known to drive the progression of breast cancer. The goal of this study was to find out which gene-expression changes were associated with the different stages of cancer and to investigate molecular patterns associated with breast cancer progression. A quantitative analysis was performed using 1,000 records of breast cancer patients with clinical data, survival data, mutation information and gene-expression data, which were gathered from secondary data. Stage I–II patients were considered as early-stage; Stage III–IV patients were considered as advanced-stage. Appropriate parametric and non-parametric test were used to compare the clinical characteristics and between stage groups 489 gene-expression variables were evaluated. False discovery rate (FDR) multiple-testing correction was carried out using the Benjamini–Hochberg method. The significantly larger tumors, higher Nottingham Prognostic Index values, lower overall survival, and higher cancer-specific mortality rates were found in advanced stage breast cancer. DTX3, CDK1, COL22A1, HES6, DLEC1, JAG2, ARID1B, BCAS3, STAT5B, and PRKD1 were among the genes that nominally exhibited stage associated expression differences. None of the latter, however, were significant after FDR. These results suggest that the distinction between early and advanced breast cancer is strong in the clinic, and the differences in gene-expression reflect exploratory analysis. Further large-scale, balanced transcriptomic cohorts are needed to confirm these candidate genes and understand their role in progression and prognosis of breast cancer.

References

1.Alharbi, R. (2020). Breast cancer gene expression profiles (METABRIC) [Data set]. Kaggle. https://www.kaggle.com/datasets/raghadalharbi/breast-cancer-gene-expression-profiles-metabric.

2.Alves, M. T., da Conceição, I. M. C. A., de Oliveira, A. N., Oliveira, H. H. M., Soares, C. E., de Paula Sabino, A., ... & Gomes, K. B. (2022). microRNA miR-133a as a biomarker for doxorubicin-induced cardiotoxicity in women with breast cancer: a signaling pathway investigation. Cardiovascular Toxicology, 22(7), 655-662.

3.Chen, F., Wang, Y., Zhang, X., & Fang, J. (2023). Five hub genes contributing to the oncogenesis and trastuzumab-resistance in gastric cancer. Gene, 851, 146942.

4.Chen, X., Wang, Y., Li, Y., Liu, G., Liao, K., & Song, F. (2022). Identification of immune-related cells and genes in the breast invasive carcinoma microenvironment. Aging (Albany NY), 14(3), 1374.

5.Chhichholiya, Y., Ruthuparna, M., Velagaleti, H., & Munshi, A. (2023). Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood–brain barrier and treatment strategies. Clinical and Translational Oncology, 25(5), 1218-1241.

6.Ding, R., Liu, Q., Yu, J., Wang, Y., Gao, H., Kan, H., & Yang, Y. (2023). Identification of breast cancer subtypes by integrating genomic analysis with the immune microenvironment. ACS omega, 8(13), 12217.

7.Ding, W., Lv, D., Wang, M., & Pei, D. (2024). IBSP Promotes Breast Cancer Bone Metastasis and Proliferation via BMP‐SMAD Signaling Pathway. Cancer Reports, 7(8), e2153.

8.Elmetwalli, A., El-Sewedy, T., Hassan, M. G., Abdel-Monem, M. O., Hassan, J., Ismail, N. F., ... & El-Far, A. H. (2025). Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-κB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(6), 7087-7105.

9.Gao, F., Liu, S., Wang, J., Wei, G., Yu, C., Zheng, L., ... & Song, Z. (2024). TSP50 facilitates breast cancer stem cell-like properties maintenance and epithelial-mesenchymal transition via PI3K p110α mediated activation of AKT signaling pathway. Journal of Experimental & Clinical Cancer Research, 43(1), 201.

10.Guo, Q., Qiu, P., Pan, K., Liang, H., Liu, Z., & Lin, J. (2024). Integrated machine learning algorithms identify KIF15 as a potential prognostic biomarker and correlated with stemness in triple-negative breast cancer. Scientific Reports, 14(1), 21449.

11.Han, B., Zhang, H., Tian, R., Liu, H., Wang, Z., Wang, Z., ... & Zhang, F. (2022). Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling. Theranostics, 12(9), 4127.

12.Hu, W., Hu, Y., Pei, Y., Li, R., Xu, F., Chi, X., ... & Yang, C. (2023). Silencing DTX3L inhibits the progression of cervical carcinoma by regulating PI3K/AKT/mTOR signaling pathway. International Journal of Molecular Sciences, 24(1), 861.

13.Jin, X., Wang, D., Lei, M., Guo, Y., Cui, Y., Chen, F., ... & Chen, X. (2022). TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5. Journal of translational medicine, 20(1), 191.

14.Jing, X., Han, C., Li, Q., Li, F., Zhang, J., Jiang, Q., ... & Huang, C. (2023). IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1870(8), 119542.

15.Li, Y. Q., Sun, F. Z., Li, C. X., Mo, H. N., Zhou, Y. T., Lv, D., ... & Ma, F. (2023). RARRES2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer. Military Medical Research, 10(1), 34.

16.Liang, Y., Wang, Y., Zhang, Y., Ye, F., Luo, D., Li, Y., ... & Yang, Q. (2023). HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer. Cell Death & Disease, 14(7), 434.

17.Liao, Y., Luo, Z., Liu, Y., Xue, W., He, S., Chen, X., ... & Guo, H. (2023). Total flavonoids of Litchi seed attenuate stem cell-like properties in breast cancer by regulating Notch3 signaling pathway. Journal of Ethnopharmacology, 305, 116133.

18.Long, L., Wang, L., Liang, Y., Ye, F., Jin, Y., Luo, D., ... & Yang, Q. (2025). UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation. Translational Oncology, 52, 102241.

19.Sha, R., Dong, X., Yan, S., Dai, H., Sun, A., You, L., & Guo, Z. (2024). Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer. Scientific Reports, 14(1), 2908.

20.Song, X., Wei, C., & Li, X. (2022). The signaling pathways associated with breast cancer bone metastasis. Frontiers in Oncology, 12, 855609.

21.Wang, B., Xing, A. Y., Li, G. X., Liu, L., & Xing, C. (2024). SNHG14 promotes triple‐negative breast cancer cell proliferation, invasion, and chemoresistance by regulating the ERK/MAPK signaling pathway. IUBMB life, 76(12), 1295-1308.

22.Wang, D., Yang, S., Lyu, M., Xu, L., Zhong, S., & Yu, D. (2024). Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway. Breast Cancer Research, 26(1), 105.

23.Wang, J., Liu, X., Li, P., Wang, J., Shu, Y., Zhong, X., ... & Yang, G. (2022). Long noncoding RNA HOTAIR regulates the stemness of breast cancer cells via activation of the NF-κB signaling pathway. Journal of Biological Chemistry, 298(12).

24.Wang, M., Wu, Y., Li, X., Dai, M., & Li, S. (2023a). IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NFκB signaling pathway. International journal of oncology, 63(3), 1-17.

25.Wang, R., Yu, H., Chen, P., Yuan, T., & Zhang, J. (2023b). Integrated transcriptome and molecular docking to identify the hub superimposed attenuation targets of curcumin in breast cancer cells. International Journal of Molecular Sciences, 24(15), 12479.

26.Wu, L., Huang, S., Tian, W., Liu, P., Xie, Y., Qiu, Y., ... & Xie, X. (2024). PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer. Cell Death Discovery, 10(1), 7.

27.Xia, W., Chen, W., Ni, C., Meng, X., Wu, J., Yang, Q., ... & Fang, S. (2023). Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway. Breast Cancer Research, 25(1), 85.

28.Yang, M., Huang, H., Zhang, Y., Wang, Y., Zhao, J., Lee, P., ... & Qu, S. (2024). Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer. Scientific Reports, 14(1), 31543.

Yousefi, H., Bahramy, A., Zafari, N., Delavar, M. R., Nguyen, K., Haghi, A., ... & Babashah, S. (2022). Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer. BMC cancer, 22(1), 1282.

Downloads

Published

2026-10-25